AG Labrador Announces $29.6 Million Settlement with Glenmark Over Conspiracy to Inflate Prices, Limit Competition

BOISE, ID – Attorney General Raúl Labrador joined a coalition of 48 states and territories announcing a $29.6 million settlement with Glenmark to resolve allegations that the generic drug manufacturer engaged in a long-running conspiracy to artificially inflate prices, reduce competition, and unreasonably restrain trade with numerous generic prescription drugs. As part of the settlement agreement, Glenmark will cooperate in the ongoing multistate litigations against 33 corporate defendants and 25 individual executives. The company has further agreed to a series of internal reforms to ensure compliance with antitrust laws. 
 
“These drug companies conspired to rig prices and eliminate competition, forcing Idaho consumers to pay artificially inflated costs for critical medications,” said Attorney General Labrador. “We will continue to pursue corporate defendants who participated in this illegal scheme that harms our families. Any Idahoan who paid for these generic drugs should file a claim for compensation.”
 
The Glenmark settlement follows settlements with Lannett, Bausch, Apotex and Heritage totaling $66.95 million.  This latest settlement comes as the States prepare for the first trial to be held in Hartford, Connecticut and anticipated to be scheduled in late 2026. 
  
The case was built on evidence from several cooperating witnesses, a document database of over 20 million records, and phone records containing millions of call details and contact information for over 600 sales and pricing individuals in the industry. Each complaint lays out an interconnected web of competing industry executives that met with each other during industry dinners, “girls nights out,” lunches, cocktail parties, golf outings and communicated via frequent telephone calls, emails and text messages that sowed the seeds for their illegal agreements. Throughout the complaints, defendants use terms like “fair share,” “playing nice in the sandbox,” and “responsible competitor” to describe how they unlawfully discouraged competition, raised prices and enforced an ingrained culture of collusion.
 
Idahoans who purchased a generic prescription drug listed here between May 2009 and December 2019 may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com.
 
Idaho is one of only two states in the multistate coalition that also secured restitution for businesses impacted by the price-fixing conspiracies. Businesses in Idaho that indirectly purchased (i.e., purchased the drug from someone other than the manufacturer), paid for, and/or provided reimbursement for some or all of the purchase price for one of more of the generic prescription drugs listed here between May 2009 and December 2019 may also be eligible for compensation. For more information, visit: https://www.aggenericdrugs.com/English/CorporateEntities.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.